Your browser doesn't support javascript.
loading
Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali.
Baya, Bocar; Achenbach, Chad J; Kone, Bourahima; Toloba, Yacouba; Dabitao, Djeneba K; Diarra, Bassirou; Goita, Drissa; Diabaté, Seydou; Maiga, Mamoudou; Soumare, Dianguina; Ouattara, Khadidia; Kanoute, Tenin; Berthe, Gaoussou; Kamia, Youssouf M; Sarro, Yeya Dit Sadio; Sanogo, Moumine; Togo, Antieme C G; Dembele, Bindongo P P; Coulibaly, Nadie; Kone, Amadou; Akanbi, Maxwell; Belson, Michael; Dao, Sounkalo; Orsega, Susan; Siddiqui, Sophia; Doumbia, Seydou; Murphy, Robert L; Diallo, Souleymane.
Afiliação
  • Baya B; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali. Electronic address: bbaya@icermali.org.
  • Achenbach CJ; Northwestern University, Chicago, IL, USA. Electronic address: c-achenbach@northwestern.edu.
  • Kone B; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: bkone@icermali.org.
  • Toloba Y; Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali. Electronic address: toloba71@yahoo.fr.
  • Dabitao DK; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: ddabitao@icermali.org.
  • Diarra B; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: bdiarra@icermali.org.
  • Goita D; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: dgoita@icermali.org.
  • Diabaté S; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: seydoudiabate@icermali.org.
  • Maiga M; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Northwestern University, Chicago, IL, USA. Electronic address: mamoudou.maiga@northwestern.edu.
  • Soumare D; Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali. Electronic address: dianguinasoumare@yahoo.fr.
  • Ouattara K; Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali. Electronic address: zankhadi@gmail.com.
  • Kanoute T; Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali. Electronic address: drtenin_kanoute@yahoo.fr.
  • Berthe G; Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali. Electronic address: gnirengolo@gmail.com.
  • Kamia YM; Department of Pneumo-phtisiology, University Teaching Hospital of Point G, Bamako, Mali. Electronic address: ykamian@yahoo.fr.
  • Sarro YDS; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: sadio@icermali.org.
  • Sanogo M; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: smoumine@icermali.org.
  • Togo ACG; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: togoacg@icermali.org.
  • Dembele BPP; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: bindongopp@gmail.com.
  • Coulibaly N; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: nadie@icermali.org.
  • Kone A; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: amadoukone@icermali.org.
  • Akanbi M; Northwestern University, Chicago, IL, USA. Electronic address: Maxwell_akanbi@yahoo.fr.
  • Belson M; National Institute of Allergic and Infectious Diseases (NIAID), Rockville, MD, USA. Electronic address: Michael.belson@nih.gov.
  • Dao S; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: sounkalod@icermali.org.
  • Orsega S; National Institute of Allergic and Infectious Diseases (NIAID), Rockville, MD, USA. Electronic address: sorsega@niaid.nih.gov.
  • Siddiqui S; National Institute of Allergic and Infectious Diseases (NIAID), Rockville, MD, USA. Electronic address: ssiddiqui@niaid.nih.gov.
  • Doumbia S; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: sdoumbi@icermali.org.
  • Murphy RL; Northwestern University, Chicago, IL, USA. Electronic address: r-murphy@northwestern.edu.
  • Diallo S; University Clinical Research Center (UCRC)-SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. Electronic address: solo@icermali.org.
Int J Infect Dis ; 81: 149-155, 2019 Apr.
Article em En | MEDLINE | ID: mdl-30772470
ABSTRACT

BACKGROUND:

MDR-TB is a major threat to global TB control. In 2015, 580,000 were treated for MDR-TB worldwide. The worldwide roll-out of GeneXpert MTB/RIF® has improved diagnosis of MDR-TB; however, in many countries laboratories are unable to assess drug resistance and clinical predictors of MDR-TB could help target suspected patients. In this study, we aimed to determine the clinical factors associated with MDR-TB in Bamako, Mali.

METHODS:

We performed a cross-sectional study of 214 patients with presumed MDR-TB admitted to University of Bamako Teaching Hospital, Point-G between 2007 and 2016. We calculated crude and adjusted odds ratios for MDR-TB disease diagnosis using SPSS.

RESULTS:

We found that age ≤40years (OR=2.56. 95% CI 1.44-4.55), two courses of prior TB treatment (OR=3.25, 95% CI 1.44-7.30), TB treatment failure (OR=3.82, 95% CI 1.82-7.79), sputum microscopy with 3+ bacilli load (OR=1.98, 95% CI 1.13-3.48) and a history of contact with a TB patient (OR=2.48, 95% CI 1.11-5.50) were significantly associated with confirmation of MDR-TB disease. HIV was not a risk factor for MDR-TB (aOR=0.88, 95% CI 0.34-1.94).

CONCLUSION:

We identified several risk factors that could be used to identify MDR-TB suspects and prioritize them for laboratory confirmation. Prospective studies are needed to understand factors associated with TB incidence and clinical outcomes of TB treatment and disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos Tipo de estudo: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Infect Dis Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos Tipo de estudo: Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Infect Dis Ano de publicação: 2019 Tipo de documento: Article